1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID 6463

Awaiting development [GID-TA11590] Expected publication date: TBC

  • Project information
  • Project documents

38344-Epcoritamab-for-Large-B-Cell-Lymphoma-V1.0-MAY2024-NON-CONF.pdf (nihr.ac.uk)